On June 12, 2026, Ionis Pharmaceuticals presented positive long-term data from the CORE-OLE open-label extension study evaluating olezarsen in patients with severe hypertriglyceridemia. Results from 53 patients who completed 12 months of treatment showed mean hepatic fat fraction (HFF) levels returning toward baseline after 24 months of the 80 mg dose. The study reported a favorable safety profile and high patient retention, with over 90% of eligible patients remaining in the extension. Ionis is a biotechnology company that develops RNA-targeted therapeutics.
